# US 2016/0355828 A1 · Organic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355828 A1
- Document ID: US20160355828A1
- Status: Published application
- Kind: A1
- Application number: 15/233,726
- Filed: 2016-08-10
- Published: 2016-12-08
- Earliest claimed: 2007-12-21
- Assignees: Novartis AG
- Inventors: Yehuda G. Assaraf; Thomas Jostock; Hans-Peter Knopf
- Web page: https://patentgrep.com/patent/US20160355828A1

## CPC

- C12N 15/64: General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 15/1079: {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N15/1086)}
- C12N 15/65: using markers (enzymes used as markers C12N15/52)
- C12N 15/85: for animal cells
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake.

## Claims

### Claim 1

A eukaryotic expression vector comprising a first polynucleotide encoding a functional membrane-bound folate receptor and a second polynucleotide encoding a product of interest.

### Claim 2 (depends on 1)

The eukaryotic expression vector according to claim 1, wherein the product of interest is selected from the group consisting of a polypeptide, a RNA and a DNA.

### Claim 3 (depends on 2)

The eukaryotic expression vector according to claim 2, wherein the product of interest is a polypeptide.

### Claim 4 (depends on 1)

The expression vector according to claim 1, wherein the first polynucleotide and the second polynucleotide are under the control of distinct transcription promoters.

### Claim 5 (depends on 4)

The expression vector according to claim 4, wherein the transcription promoters are the same.

### Claim 6 (depends on 4)

The expression vector according to claim 4, wherein the transcription promoters are different.

### Claim 7 (depends on 4)

The expression vector according to claim 4, wherein the promoter controlling the transcription of the first polynucleotide is an SV40 promoter.

### Claim 8 (depends on 1)

The expression vector according to claim 1, wherein the first polynucleotide and the second polynucleotide are under the control of a common transcription promoter.

### Claim 9 (depends on 8)

The expression vector according to claim 8, wherein the common transcription promoter is an SV40 promoter.

### Claim 10 (depends on 8)

The expression vector according to claim 8, wherein said vector comprises an IRES element functionally located between the first polynucleotide and the second polynucleotide.

### Claim 11 (depends on 1)

The expression vector according to claim 1, wherein the functional membrane-bound folate receptor encoded by the first polynucleotide is selected from the group consisting of a folate receptor alpha (FRα), a folate receptor beta (FRβ), and a functional mutant thereof.

### Claim 12 (depends on 11)

The expression vector according to claim 11, wherein the functional membrane-bound folate receptor encoded by the first polynucleotide is a human folate receptor alpha (hFRα).

### Claim 13

A eukaryotic cell for which cellular viability is dependent on folate uptake, and into which eukaryotic cell a first polynucleotide located on an expression vector and encoding a functional membrane-bound folate receptor and a second polynucleotide located on an expression vector and encoding a product of interest have been stably introduced, wherein the first polynucleotide and the second polynucleotide are located on the same expression vector or on separate an expression vectors.

### Claim 14 (depends on 13)

The eukaryotic cell according to claim 13, wherein said cell is lacking full activity of at least one endogenous functional membrane-bound folate receptor.

### Claim 15 (depends on 13)

The eukaryotic cell according to claim 13, wherein said first polynucleotide encoding a functional membrane-bound folate receptor and said second polynucleotide encoding a product of interest are located on the same expression vector.

### Claim 16 (depends on 1, 13)

The eukaryotic cell according to claim 13, wherein the expression vector is as defined in claim 1.

### Claim 17 (depends on 13)

The eukaryotic cell according to claim 13, wherein said eukaryotic cell is a mammalian cell.

### Claim 18 (depends on 17)

The eukaryotic cell according to claim 17, wherein said mammalian cell is a rodent cell.

### Claim 19 (depends on 18)

The eukaryotic cell according to claim 18, wherein said rodent cell is a CHO cell.

### Claim 20 (depends on 13)

A process for production of a eukaryotic cell according to claim 13, said process comprising providing an eukaryotic cell for which cellular viability is dependent upon folate uptake, and introducing a first polynucleotide located on an expression vector and encoding the functional membrane-bound folate receptor and a second polynucleotide located on an expression vector and encoding the product of interest, wherein the first polynucleotide and the second polynucleotide are located on the same expression vector or on separate an expression vectors.

### Claim 21 (depends on 20)

The process according to claim 20, wherein the first polynucleotide and the second polynucleotide are located on the same expression vector.

### Claim 22 (depends on 1, 21)

The process according to claim 21, wherein the expression vector is as defined in claim 1.

### Claim 23

A method for selection of a eukaryotic cell capable of stably expressing a product of interest encoded by an expression vector which has been introduced into the cell, comprising
(i) providing a plurality of eukaryotic cells for which cellular viability is dependent upon folate uptake, and into which cells a first polynucleotide located on an expression vector and encoding a functional membrane-bound folate receptor and a second polynucleotide located on an expression vector and encoding the product of interest have been introduced, wherein the first polynucleotide and the second polynucleotide are located on the same expression vector or on separate expression vectors,
(ii) culturing said plurality of eukaryotic cells in a cell culture medium having a limiting concentration of a folate, thereby obtaining a eukaryotic cell wherein stable expression of the product of interest is achieved.

### Claim 24 (depends on 23)

The method according to claim 23, further comprising identifying and isolating a eukaryotic cell wherein stable expression of the product of interest is achieved.

### Claim 25 (depends on 13, 23)

The method according to claim 23, wherein the plurality of eukaryotic cells is composed of eukaryotic cells as defined in claim 13.

### Claim 26 (depends on 23)

A process for production of a product of interest, comprising
(i) performing a method of selection according to claim 23,
(ii) and isolating the product of interest from said cell culture medium or from said cell.

### Claim 27

A method for selection of a eukaryotic cell capable of stably expressing a product of interest comprising the use of a functional membrane bound folate receptor as a section marker, wherein said eukaryotic cell cellular viability is dependent on the uptake of folate.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the folate receptor is selected from the group consisting of the folate receptor alpha (FRα), the folate receptor beta (FRβ), and a functional mutant thereof.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the folate receptor is the human folate receptor alpha (hFRα).
